Test Price
2,800 AED✅ Home Collection Available
GUCA1A Gene Cone-Rod Dystrophy Type 14 NGS Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- 99.9% Diagnostic Sensitivity – ISO 9001:2015 accredited NGS processing, validated per international clinical standards.
- Premium Home Collection – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance – Post-test telephonic result interpretation by a DHA-licensed consultant medical genetics specialist.
- Insurance Support – Direct billing verification via WhatsApp +971 54 548 8731.
Corporate Oversight
This test is conducted at DNA Labs UAE, DHA Facility License No. 1143, under the clinical supervision of Consultant Medical Genetics Lina Osama Zaki Quteineh (DHA ID: 9294403). Our laboratory operates in full compliance with the UAE Personal Data Protection Law (PDPL) and health data regulations.
Test Overview & Methodology
This state-of-the-art NGS test screens the full coding sequence of the GUCA1A gene to identify pathogenic variants causing cone-rod dystrophy type 14, a progressive inherited retinal disorder affecting central vision. The test provides a definitive molecular diagnosis, enabling accurate prognosis, surveillance planning, and informed family counseling.
| Parameter | Our GUCA1A NGS Test | Closest Alternative |
|---|---|---|
| Precision | Full gene sequencing, >99.9% analytical sensitivity | Single-exon or PCR-based methods (limited coverage) |
| Methodology | Next Generation Sequencing (NGS) – Illumina platform | Sanger sequencing of selected exons |
| Turnaround Time | 3–4 weeks | 4–6 weeks or more with reflex testing |
| Pre-Test Genetic Counselling | Included, with pedigree analysis | Often not standardised |
Physician Insight & Safety Protocols
“Identifying a pathogenic GUCA1A variant through NGS provides a definitive molecular anchor for managing cone-rod dystrophy type 14. This result must be integrated with a comprehensive ophthalmologic and electrophysiological assessment. Even if the test is negative, ongoing clinical surveillance remains vital, as other genetic or acquired etiologies can produce similar phenotypes.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Warning:
Advisory Notice
Do not discontinue or alter any prescribed medications without direct consultation with your treating physician. This genetic test is not designed to evaluate drug interactions, response profiles, or contraindications for any therapy.
Safety Exclusion Criteria & Emergency Red Flags
- Inability to provide informed consent (or guardian consent for minors as per UAE Child Rights Law – Wadeema’s Law).
- Acute febrile illness or active systemic infection that may compromise sample integrity.
- Severe coagulopathy or bleeding disorder contraindicating venipuncture.
- Age below 18 years without legal guardian accompaniment.
If you experience sudden vision loss, severe eye pain, or retinal detachment symptoms, seek emergency ophthalmic care immediately — this test is for genetic risk assessment, not acute intervention.
Patient FAQ & Clinical Guidance
1. What is the clinical purpose of the GUCA1A gene test for cone-rod dystrophy type 14?
This test identifies pathogenic variants in GUCA1A that cause autosomal dominant cone-rod dystrophy type 14, confirming clinical suspicion and guiding prognosis, surveillance, and family planning.
2. How is the sample collected and what is the turnaround time?
A standard peripheral whole blood sample is collected via our VIP Mobile Phlebotomy service at your home. The sample is transported under strict temperature-controlled cold-chain conditions. Results are delivered within 3 to 4 weeks.
3. Can this genetic test be used for prenatal diagnosis or preimplantation genetic testing?
When a familial GUCA1A mutation is known, this test can be adapted for prenatal diagnosis or preimplantation genetic diagnosis in collaboration with a clinical genetics clinic, in full compliance with UAE medical liability laws (Federal Decree-Law No. 4 of 2016) and applicable health regulations.
4. Does insurance cover the cost of this test?
Coverage varies by your insurance plan. Our team can verify your eligibility and provide direct billing support. Contact us via WhatsApp at +971 54 548 8731 for a personalized pre-authorization check.
UAE Regulatory & Data Privacy Adherence
This genetic testing service operates under the framework of:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring the security and confidentiality of your genetic information.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing the safe handling of digital health records.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – upholding the highest standards of clinical care and patient safety.
All test data is stored on encrypted servers and processed solely for diagnostic and clinical advisory purposes. Your rights to access, rectify, or restrict processing of your data are fully protected under PDPL.
Clinical & Logistical Metadata
| Test Name | GUCA1A Gene Cone-Rod Dystrophy Type 14 NGS Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 – 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood |
| Methodology Used | Next Generation Sequencing (NGS) |
| ICD-10-CM Code | H35.54 |
| LOINC Code | 100347-5 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians